EMERALD2

The purpose of this study is to learn about the safety and effectiveness of a new experimental drug called MORF-057. This study will also look at the way the body absorbs, distributes, and gets rid of the study drug (called pharmacokinetics, or PK) and the way the study drug affects the body (called pharmacodynamics, or PD).
 

Category
Trial Status
Recruiting
Trial Phase
Phase 2 Drug Trial
ERM Project ID
92237
Trial contact details
Contact Person
Sharyn Grossman
What you need to know

To participate you must:
- Be aged 18 - 85
- Have diagnosed UC for at least 3 months verified by endoscopy & histology
- Have been on previous therapy that you had to cease
- Have had a colonoscopy in the last 2 years
- BMI > 18
- Have blood test results in normal ranges
-Meet all the detailed inclusion/exclusion criteria

You must not:
- Have another bowel condition
- Have surgery planned for during the study
- Have a neurological condition
- Have an active infection
- Have a history of malignancy
- Some medications may cause you to be ineligible

 

What is involved for me?

- 11 study visits across 14 months
- blood tests, urine tests & stool tests
- Daily eDiary completion
- ECG x 4
- Flexible Sigmoidoscopy x 3
- Daily oral medication

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|